The Global Antibiotics Active Pharmaceutical Ingredients (API) Industry is on track for a consistent rise, driven by the continued need for effective treatments against bacterial infections. According to a recent industry analysis, the market is expected to reach a significant value of US$8,653.0 million by the end of 2023. Looking ahead, the market is projected to climb further to an impressive US$12,002.3 million by 2033. This upward trajectory reflects a Compound Annual Growth Rate (CAGR) of 3.3%, highlighting the ongoing demand for antibiotics across the healthcare landscape.
At the heart of this unparalleled growth lies the escalating prevalence of bacterial infections and various infectious diseases on a global scale. The rising number of individuals grappling with these conditions has led to a surge in demand for antibiotic medications, thereby serving as a driving force behind the industry’s expansion.
Request a Sample of this Report Using a Work Email To Get a Quick Reply!
https://www.futuremarketinsights.com/reports/sample/rep-gb-13025
The COVID-19 pandemic is anticipated to have a detrimental effect on the market for antibiotic APIs. Several of the biggest pharmaceutical companies, research universities, and biotech companies have been chosen to address the issue. They are now focusing on creating coronavirus vaccines rather than other drugs as a result. Hospital beds are scarce, and several APIs are in short supply.
Due to the rising demand and widespread use of penicillin as a first-line antibiotic therapy to treat various bacterial infections, the penicillin antibiotics segment dominated the antibiotics API market in 2021 with a market share of 51.1%. It is anticipated that pharmaceutical corporations will dominate the end-user market. Through the projected period, they are anticipated to hold more than 77% of the market and continue to dominate.
Key Takeaways from Global Antibiotics Active Pharmaceutical Ingredients (API) Industry Study
- The Global Antibiotics Active Pharmaceutical Ingredient Industry market is estimated to be US$ 8.653 Bn in 2023, with the market expected to exhibit a CAGR of 3.3% during the forecast period (2023-2033)
- The U.S. holds over 92.1% share of the North American market, but Canada is projected to expand faster CAGR
- The U.K. market will showcase steady y-o-y growth at 2.1% in 2021
- The demand from Germany and France will rise at a positive rate through the forecast period
- Within East Asia China will emerge as a key market, while Japan and South Korea will continue exhibiting steady demand
“Increasing prevalence of bacterial diseases, extreme use of antibiotics and rising investment in R&D are expected to boost the growth of the Global Antibiotics Active Pharmaceutical Ingredient Industry.” says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)
Rising investment in the R&D sector to develop advanced molecules is the major factor expected to boost the antibiotic API market growth.
For instance, Sandoz, the Novartis biosimilars and generics division, undergoes a joint investment, with the Austrian federal government, to enhance the long-term future of integrated antibiotics manufacturing in Europe.
Key players in the Global Antibiotics Active Pharmaceutical Ingredients (API) Industry are Entering into the Strategic Alliance
The top players are focusing on increasing acquisitions at regional levels. Acquisitions empower the company with products and increase the company’s portfolio. The company acquires well-established products and solutions that are expected to account for good revenue sources for the acquirer. This also enables the company to enter new emerging markets as well as enhance the existing markets.
For instance, in August 2019, Nanjing Dorra Pharmaceutical Technology collaborated with Meitheal Pharmaceuticals, the fully integrated generic injectables company, to elevate the manufacturing capacity of active pharmaceutical ingredients in the region of the U.S. The collaboration enabled Meitheal Pharmaceuticals to invest in Nanjing Dorra Pharmaceutical Technology.
Request Your Customized Report Now!
https://www.futuremarketinsights.com/customization-available/rep-gb-13025
Who is Winning?
The Global Antibiotics Active Pharmaceutical Ingredient Industry is set to expand its scope in the forecast period, as a result of the rising prevalence of various bacterial diseases, and growing investment in R&D. The antibiotics market is highly competitive and consists of several major players. Pharmaceutical companies are more focused on outsourcing antibiotics API manufacturing due to the involvement of high capital investment in the establishment of Global Antibiotics Active Pharmaceutical Ingredient Industry manufacturing units.
The key market players covered by FMI include Sandoz International GmbH, Centrient Pharmaceuticals, CordenPharma International, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., DAEWOONG PHARMACEUTICAL CO. LTD., Parabolic Drugs Ltd., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., and Kyongbo Pharm, consolidating their positions through mergers, acquisitions and new product launches.
Global Antibiotics Active Pharmaceutical Ingredients (API) Industry by API Type:
API Type
- Penicillin Antibiotics
- Ampicillin
- Amoxicillin
- Dicloxacillin
- Penicillin G Sodium
- Benzathine
- Procaine
- Cephalosporins
- Cefotaxime
- Ceftriaxone
- Cefuroxime
- Cefalotin
- Carbapenem Antibiotics
- Meropenem
- Imipenem
- Ertapenem
End User
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Contract Development & Manufacturing Organizations (CDMOs)
Click Here To Purchase Your Full Report
https://www.futuremarketinsights.com/checkout/13025
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube